NEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TransAct Technologies Incorporated (NASDAQ:TACT), Lifeway Foods, Inc. (NASDAQ:LWAY), ImmuCell Corporation (NASDAQ:ICCC), Digirad Corporation (NASDAQ:DRAD), Destination Maternity Corporation (NASDAQ:DEST), and Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
TACT DOWNLOAD: http://Fundamental-Markets.com/register/?so=TACT
LWAY DOWNLOAD: http://Fundamental-Markets.com/register/?so=LWAY
ICCC DOWNLOAD: http://Fundamental-Markets.com/register/?so=ICCC
DRAD DOWNLOAD: http://Fundamental-Markets.com/register/?so=DRAD
DEST DOWNLOAD: http://Fundamental-Markets.com/register/?so=DEST
TTNP DOWNLOAD: http://Fundamental-Markets.com/register/?so=TTNP
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine TransAct Technologies Incorporated (NASDAQ:TACT), Lifeway Foods, Inc. (NASDAQ:LWAY), ImmuCell Corporation (NASDAQ:ICCC), Digirad Corporation (NASDAQ:DRAD), Destination Maternity Corporation (NASDAQ:DEST), and Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
TRANSACT TECHNOLOGIES INCORPORATED (TACT) REPORT OVERVIEW
TransAct Technologies' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, TransAct Technologies reported revenue of $11.76MM vs $13.19MM (down 10.91%) and analysts estimated basic earnings per share $0.13 vs -$0.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, TransAct Technologies reported revenue of $54.59MM vs $56.31MM (down 3.06%) and analysts estimated basic earnings per share $0.73 vs $0.43 (up 69.77%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.09.
To read the full TransAct Technologies Incorporated (TACT) report, download it here: http://Fundamental-Markets.com/register/?so=TACT
-----------------------------------------
LIFEWAY FOODS, INC. (LWAY) REPORT OVERVIEW
Lifeway Foods' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Lifeway Foods reported revenue of $23.03MM vs $26.26MM (down 12.28%) and analysts estimated basic earnings per share -$0.17 vs -$0.11. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Lifeway Foods reported revenue of $103.35MM vs $118.89MM (down 13.07%) and analysts estimated basic earnings per share -$0.19 vs -$0.02. Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Lifeway Foods, Inc. (LWAY) report, download it here: http://Fundamental-Markets.com/register/?so=LWAY
-----------------------------------------
IMMUCELL CORPORATION (ICCC) REPORT OVERVIEW
ImmuCell's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, ImmuCell reported revenue of $2.94MM vs $3.13MM (down 6.25%) and analysts estimated basic earnings per share -$0.18 vs -$0.03. For the twelve months ended December 31st, 2018 vs December 31st, 2017, ImmuCell reported revenue of $10.99MM vs $10.43MM (up 5.32%) and analysts estimated basic earnings per share -$0.42 vs -$0.03. Analysts expect earnings to be released on May 13th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full ImmuCell Corporation (ICCC) report, download it here: http://Fundamental-Markets.com/register/?so=ICCC
-----------------------------------------
DIGIRAD CORPORATION (DRAD) REPORT OVERVIEW
Digirad's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Digirad reported revenue of $25.93MM vs $26.31MM (down 1.46%) and basic earnings per share -$0.07 vs -$1.11. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Digirad reported revenue of $104.18MM vs $104.63MM (down 0.43%) and analysts estimated basic earnings per share $0.04 vs -$1.79. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Digirad Corporation (DRAD) report, download it here: http://Fundamental-Markets.com/register/?so=DRAD
-----------------------------------------
DESTINATION MATERNITY CORPORATION (DEST) REPORT OVERVIEW
Destination Maternity's Recent Financial Performance
For the three months ended October 31st, 2018 vs October 31st, 2017, Destination Maternity reported revenue of $92.84MM vs $96.35MM (down 3.65%) and analysts estimated basic earnings per share -$0.30 vs -$0.55. For the twelve months ended January 31st, 2018 vs January 31st, 2017, Destination Maternity reported revenue of $406.21MM vs $433.70MM (down 6.34%) and analysts estimated basic earnings per share -$1.57 vs -$2.39. Analysts expect earnings to be released on June 13th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $0.07.
To read the full Destination Maternity Corporation (DEST) report, download it here: http://Fundamental-Markets.com/register/?so=DEST
-----------------------------------------
TITAN PHARMACEUTICALS, INC. (TTNP) REPORT OVERVIEW
Titan Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Titan Pharmaceuticals reported revenue of $1.24MM vs $0.06MM (up 2,031.03%) and analysts estimated basic earnings per share -$0.02 vs -$1.05. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Titan Pharmaceuticals reported revenue of $6.62MM vs $0.22MM (up 2,978.14%) and analysts estimated basic earnings per share -$1.64 vs -$4.05. Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.72. The estimated EPS forecast for the next fiscal year is -$0.09 and is expected to report on April 6th, 2020.
To read the full Titan Pharmaceuticals, Inc. (TTNP) report, download it here: http://Fundamental-Markets.com/register/?so=TTNP
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Arden Dalio, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.